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Abstract: Bazedoxifene, a novel selective estrogen receptor modulator, has been developed to 
have favorable effects on bone and the lipid profile while minimizing stimulation of uterine or 
breast tissues. Two large Phase III clinical trials showed that bazedoxifene, as well as raloxifene, 
increased bone mineral density, decreased levels of bone turnover markers, and significantly 
reduced the risk of new vertebral fractures in postmenopausal women compared with placebo. 
Although the incidence of nonvertebral fractures with bazedoxifene or raloxifene did not differ 
significantly from that with placebo, a post hoc analysis of a subgroup of women at higher fracture 
risk revealed that bazedoxifene significantly reduced the nonvertebral fracture risk relative to 
placebo and raloxifene. Bazedoxifene also improved the lipid profile by reducing the serum 
concentrations of total cholesterol and low-density lipoprotein cholesterol, with an increase 
in the serum level of high-density lipoprotein cholesterol. The incidences of vasodilatation 
(hot flushes), leg cramps, and venous thromboembolic events were significantly higher with 
bazedoxifene and raloxifene compared with placebo. There was no evidence of endometrial and 
breast stimulation with bazedoxifene. Taking advantage of the favorable effects of bazedoxifene 
on the breast and endometrium, the pairing of bazedoxifene with conjugated estrogens is under 
investigation for the treatment of menopausal symptoms and prevention of postmenopausal 
osteoporosis. A Phase III trial showed that combination therapy of bazedoxifene and conjugated 
estrogens significantly increased bone mineral density and decreased bone turnover markers, 
with relief of hot flushes and improvement of vaginal atrophy. This article reviews the clinical 
efficacy and safety of bazedoxifene in the treatment of postmenopausal osteoporosis.
Keywords: selective estrogen receptor modulators, osteoporosis, estrogen receptor, nonvertebral 
fracture, endometrium
Introduction
Osteoporosis is a systemic skeletal disease characterized by loss of bone mass and 
strength, which leads to bone fragility and increased susceptibility to fractures.1,2 
Osteoporotic fractures, which usually occur at the spine, hip, and distal radius, impact 
negatively on quality of life and increase both morbidity and mortality.3–6 Health care 
costs for patients with osteoporotic fractures are anticipated to rise in parallel with the 
increase in elderly populations. Treatment of osteoporotic patients is important for both 
preventing osteoporotic fractures and reducing the associated health care burden.
Declining levels of endogenous estrogens mainly contribute to rapid bone loss 
at the time of menopause, leading to postmenopausal osteoporosis. It has been 
demonstrated that long-term hormone replacement therapy with estrogen plus progestin 
prevents bone loss and fractures.7,8 However, large randomized controlled trials had Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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suggested that hormone replacement therapy increased the 
risk of breast cancer, although they have demonstrated that 
hormone replacement therapy significantly reduced the risk 
of osteoporotic fractures.9 To avoid such negative aspects 
of estrogen action, selective estrogen receptor modulators 
(SERMs), which act as estrogen receptor agonists in some 
tissues and as estrogen receptor antagonists in others, have 
been developed (Figure 1). An ideal SERM would have 
beneficial agonistic effects on bone, the cardiovascular 
system, and the central nervous system to prevent bone loss 
and cardiovascular events, but have anti-estrogenic effects 
on the breast and endometrium to reduce the risk of breast 
and endometrial cancers.
Tamoxifen was the first SERM used clinically to reduce 
the risk of breast cancer in high-risk women.10,11 It was also 
reported that tamoxifen maintained bone mineral density in 
postmenopausal women.12 However, long-term treatment 
with tamoxifen increased the risks of endometrial cancer and 
blood clots, related to the partial estrogen receptor agonistic 
activity of this compound.13 Raloxifene was also found to 
be an effective estrogen receptor antagonist against breast 
cancer. In addition to its lack of proliferative effects on the 
uterus, unlike tamoxifen, raloxifene was shown to decrease 
plasma cholesterol levels and prevent decreases in bone 
mineral density.14 Raloxifene acts as an estrogen agonist in 
bone and lipid metabolism but an estrogen antagonist in the 
breast. Raloxifene is the first SERM to have been approved 
by the US Food and Drug Administration for the prevention 
and treatment of postmenopausal osteoporosis.15,16
Bazedoxifene is a third-generation SERM, which was 
recently approved for the treatment of postmenopausal 
osteoporosis in Europe and Japan. This comprehensive 
review describes the efficacy and safety of bazedoxifene in 
patients with osteoporosis.
Bazedoxifene
Bazedoxifene acetate (WAY-140424, TSE-424) is an 
indole-based estrogen receptor ligand with unique structural 
characteristics (Figure 1). The molecule was assembled by 
using raloxifene as a template and substituting an indole ring 
for the benzothioprine core.17,18 To select this novel SERM, 
a stringent selection process was implemented to assess its 
biological activity and tissue selectivity on key endpoints, 
which included the uterus, lipid metabolism, bone remodel-
ing, and central nervous system function.19–21
Preclinical research
In vitro studies
Bazedoxifene binds to both estrogen receptor alpha (ERα) and 
estrogen receptor beta (ERβ), with IC50 values of 23 ± 15 nM 
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and 85 ± 59 nM, respectively, and a slight preference for 
ERα.19,21 Its affinity for ERα is about 10-fold lower than 
that of 17β-estradiol (IC50 3 ± 1 nM) and raloxifene (IC50 
4 ± 3 nM). Bazedoxifene competitively inhibits 17β-estradiol 
binding to both ERα (dissociation constant for   bazedoxifene 
0.1 nM) and ERβ (0.3 nM). In MCF-7 breast cancer 
cells, bazedoxifene showed no estrogen receptor agonist 
activity, but inhibited 17β-estradiol-induced transcriptional 
activation.19,21 Bazedoxifene did not stimulate the prolifera-
tion of MCF-7 cells, but did inhibit 17β-estradiol-induced 
proliferation in a dose-dependent manner.19,21
effects on bone
In a 6-week ovariectomized rat model, bazedoxifene 
0.3 mg/kg/day consistently and significantly increased bone 
mass compared with control animals.19,21 The vertebral com-
pressive strength in bazedoxifene-treated ovariectomized rats 
was equivalent to or better than that in sham-operated animals 
and significantly better than that in vehicle-treated ovariec-
tomized animals.21 Bone histology was also maintained in 
bazedoxifene-treated ovariectomized rats.
endometrial effects
In an immature rat uterine model, ethinyl estradiol increased 
the wet uterine weight after 3 days of treatment. Bazedoxifene 
0.5 mg/kg and 5.0 mg/kg was associated with a smaller 
increase in wet uterine weight than either ethinyl estradiol 
or raloxifene.21 Histological examination revealed that 
bazedoxifene did not cause luminal epithelial cell hyper-
trophy or hyperplasia, myometrial hypertrophy, or luminal 
distention. Cotreatment of bazedoxifene and raloxifene 
completely abrogated stimulation of luminal epithelial cells 
and the myometrium by raloxifene, supporting an improved 
uterine profile for bazedoxifene.21 Anti-estrogenic effects of 
bazedoxifene on the endometrium were also confirmed in an 
ovariectomized mouse model.22
vasomotor effects
In a morphine-addicted rat model of vasomotor   activity, 
naloxone injection resulted in a rapid rise in tail skin 
  temperature. The increase in tail skin temperature was 
abrogated in rats pretreated with estrogen receptor agonists. 
Similar to raloxifene, bazedoxifene did not act as an estrogen 
receptor agonist in this model. When a bone-sparing dose 
(0.3 mg/kg/day) of bazedoxifene was coadministered with 
ethinyl estradiol, no antagonism was detected, which may 
indicate a potential lack of a vasomotor effect of bazedoxifene 
in postmenopausal women.21
Mammary glands
In a study comparing the relative effects of SERMs on the 
mammary gland of ovariectomized mice, bazedoxifene 
exhibited less agonist activity and was a more effective 
antagonist of conjugated estrogens in the mammary gland 
than other SERMs, ie, raloxifene and lasofoxifene, as 
assessed by both gene expression and morphology of the 
mammary gland.22
Lipid profiles
In a 6-week ovariectomized rat study, bazedoxifene 
  significantly reduced total cholesterol level as effectively 
as raloxifene.19,21
Clinical studies
Clinical pharmacokinetics and metabolism
In a Phase I dose-proportionality study in healthy 
postmenopausal women, bazedoxifene reached a maximum 
plasma concentration at 1–2 hours after oral administration, 
and its half-life was approximately 28 hours. A steady-state 
plasma concentration was achieved by day 7, and linear 
pharmacokinetics were observed in the dose range tested 
(5–40 mg).23 The metabolic profile of bazedoxifene was 
analyzed using a single oral dose of [14C]bazedoxifene 
20 mg. The major route of excretion was the feces (84.7%), 
with less than 1% excreted in the urine. The predominant 
metabolite was bazedoxifene-5-glucuronide (40%–95%).24 
There was little or no cytochrome P450-mediated metabolism 
of bazedoxifene.
Phase II clinical efficacy and safety
A 3-month, randomized, placebo-controlled study demon-
strated that bazedoxifene reduced bone turnover markers in 
healthy menopausal women (n = 494) in a dose-dependent 
manner.25 A 6-month, double-blind, randomized study of 
healthy postmenopausal women (n = 497) assessed the endo-
metrial effects of bazedoxifene.26 No significant differences 
in endometrial thickness were observed from baseline for 
bazedoxifene doses of 2.5–20 mg/day. On the other hand, 
significant decreases in endometrial thickness and decreased 
uterine bleeding were observed for bazedoxifene doses of 
30 mg and 40 mg compared with placebo.26 The incidence of 
breast pain was also significantly lower in the bazedoxifene 
40 mg group than in the placebo group.27
Phase III clinical trials
Two large, prospective, global Phase III trials of bazedoxifene 
for osteoporosis prevention and treatment have been Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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completed.28,29 Both studies were randomized, double-
blind trials and included a placebo and a positive control 
(raloxifene).
Two-year Phase III study
In a 2-year Phase III study, a total of 1583 healthy postmeno-
pausal women with a bone mineral density T score at the lum-
bar spine or femoral neck between −1.0 and −2.5 or clinical 
risk factors for osteoporosis were randomly assigned to one of 
five groups, ie, bazedoxifene 10, 20, or 40 mg/day, placebo, 
or raloxifene 60 mg/day.28 All the women received daily 
supplementation with elemental calcium 600 mg.   Compared 
with placebo, all doses of bazedoxifene and raloxifene pre-
vented bone loss at all skeletal sites. The mean differences in 
percent change in lumbar spine bone density from baseline to 
24 months relative to placebo were 1.08% ± 0.28%, 1.41% ± 
0.28%, and 1.49% ± 0.28% for bazedoxifene 10, 20, and 
40 mg, respectively (P , 0.001 for all comparisons). All the 
bazedoxifene treatment groups had significantly greater bone 
mineral density at the total hip in comparison with the placebo 
group at 6, 12, 18, and 24 months. Significant reductions 
in serum levels of osteocalcin and cross-linked C-terminal 
telopeptide of type I collagen from baseline and relative to 
placebo were observed for all doses of bazedoxifene and 
raloxifene treatment as early as 3 months, and were sustained 
until the end of the study (P , 0.001). Serum concentrations 
of total cholesterol and low-density lipoprotein cholesterol 
were decreased with bazedoxifene and raloxifene treatment 
compared with placebo, whereas serum levels of high-density 
lipoprotein cholesterol were elevated after treatment with 
the SERMs. Although significant increases from baseline 
in the median concentrations of triglycerides were observed 
among women receiving bazedoxifene 20 mg and 40 mg 
and placebo, there were no significant differences between 
the groups. The overall incidences of adverse events, serious 
adverse events, and discontinuations caused by adverse events 
were similar among the groups (Table 1). The most common 
adverse events included headache, infection, arthralgia, pain, 
hot flushes, and back pain.28
Three-year Phase III study
In a 3-year Phase III study, 7492 healthy postmenopausal 
women aged 55–85 years with osteoporosis, defined by low 
bone mineral density or radiographically confirmed vertebral 
fractures, were randomized to treatment with bazedoxifene 
20 or 40 mg/day, raloxifene 60 mg/day, or placebo.29 All 
the subjects received daily oral calcium #1200 mg and 
vitamin D 400–800 IU supplementation. The primary 
endpoint was the incidence of new vertebral fractures after 
36 months and secondary endpoints included nonvertebral 
fractures, bone mineral density, and bone turnover markers. 
Treatment with bazedoxifene 20 and 40 mg and raloxifene 
60 mg significantly increased lumbar spine and total hip 
bone mineral density (Figure 2) and reduced serum levels 
of osteocalcin and C-terminal telopeptide of type I col-
lagen compared with placebo. Among 6847 subjects in the 
intention-to-treat population, the incidence of new vertebral 
fractures was significantly lower (P , 0.05) for bazedoxifene 
20 mg (2.3%), bazedoxifene 40 mg (2.5%), and raloxifene 
60 mg (2.3%) compared with placebo (4.1%). Relative to 
Table 1 Safety profile of bazedoxifene in two Phase III trials
2-year study28 3-year study29
Adverse event, n (%) Bazedoxifenea 
(n = 962)
Raloxifene 
(n = 311)
Placebo 
(n = 310)
Bazedoxifeneb 
(n = 3758)
Raloxifene 
(n = 1849)
Placebo 
(n = 1885)
Any adverse event 916 (95.2) 309 (96.0) 297 (95.8) 3598 (95.7) 1775 (96.0) 1813 (96.2)
Any serious adverse event 99 (10.3) 29 (9.3) 28 (9.0) 750 (20.0) 344 (18.6) 353 (18.7)
Discontinuations caused by Ae 167 (17.4) 43 (13.8) 48 (15.5) 539 (14.3) 262 (14.2) 240 (12.7)
Selected adverse events
  Myocardial infarction 3 (0.3) 0 1 (0.3) 16 (0.4) 6 (0.3) 8 (0.4)
  Strokes 2 (0.2) 1 (0.3) 0 38 (1.0) 15 (0.8) 20 (1.1)
  Deep vein thrombosis 2 (0.2) 0 1 (0.3) 18 (0.5) 8 (0.4) 1 (0.1)
  Pulmonary embolus 1 (0.1) 0 0 8 (0.2) 4 (0.2) 4 (0.2)
  Retinal vein thrombosis 0 1 (0.3) 0 3 (0.1) 0 3 (0.2)
  Hot flushes 207 (21.5) 58 (18.6) 44 (14.2) 481 (12.8) 222 (12.0) 118 (6.3)
  Leg cramps 107 (11.1) 37 (11.9) 36 (11.6) 409 (10.9) 216 (11.7) 155 (8.2)
  endometrial carcinoma 0 0 1 (0.3) 2 (0.05) 2 (0.1) 3 (0.2)
  endometrial hyperplasia 0 0 0 2 (0.05) 1 (0.1) 1 (0.1)
  Breast carcinoma 3 (0.3) 1 (0.3) 2 (0.6) 9 (0.2) 7 (0.4) 8 (0.4)
Notes: aTotal number of subjects who received bazedoxifene 10, 20, or 40 mg/day; bTotal number of subjects who received bazedoxifene 20 or 40 mg/day.
Abbreviation: Ae, adverse event.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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placebo, bazedoxifene 20 mg and 40 mg and raloxifene 
60 mg reduced the risk of new vertebral fractures by 42%, 
37%, and 42%, respectively (Figure 3).29 There were no 
significant differences in the incidence of new vertebral 
fractures between the bazedoxifene and raloxifene treat-
ment groups. The incidence of nonvertebral fractures with 
bazedoxifene 20 mg (5.7%) and 40 mg (5.6%) and raloxifene 
60 mg (5.9%) did not differ significantly from placebo (6.3%, 
Figure 3). However, in a post hoc analysis of a subgroup of 
women at higher fracture risk (femoral neck T score # −3.0 
and/or at least one moderate or severe vertebral fracture or 
multiple mild vertebral fractures; n = 1772), bazedoxifene 
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Figure 2 Effects of bazedoxifene on the lumbar spine and hip BMD. (A) Mean percent changes from baseline in the lumbar spine (L1–L4) BMD. (B) Mean percent changes 
from baseline in the total hip BMD.
Notes: aP , 0.001 vs placebo at each time point; bP , 0.05 vs raloxifene at each time point; cP , 0.01 vs raloxifene at each time point.
Adapted from Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: 
Results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23(12):1923–1934, with permission from the American Society for 
Bone and Mineral Research.29
Abbreviation: BMD, bone mineral density.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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20 mg showed 50% and 44% reductions in nonvertebral 
fracture risk relative to placebo (P = 0.02) and raloxifene 
60 mg (P = 0.05), respectively (Figure 4). A similar reduc-
tion in nonvertebral fracture incidence was observed with 
bazedoxifene 40 mg, but the difference was not statistically 
significant (Figure 4).
An independent re-evaluation of fracture data from 
the Phase III study was performed using the Fracture Risk 
Assessment Tool (FRAX®) algorithm developed by the 
World Health Organization to estimate 10-year fracture 
risk.30,31 In patients with a 10-year fracture risk .6.9%, 
bazedoxifene was associated with a significant decrease 
in risk of morphometric vertebral fractures. Moreover, in 
patients with 10-year fracture probabilities at or above 16%, 
bazedoxifene was associated with a significant decrease in 
risk of all clinical fractures.31
In the 3-year Phase III trial, bazedoxifene 20 mg and 
40 mg doses were well tolerated. The incidences of adverse 
events, serious adverse events, discontinuations because of 
adverse events, and deaths in the bazedoxifene groups were 
generally similar to those in the placebo group (Table 1).29 
The most common adverse events were abdominal pain, 
accidental injury, arthralgia, back pain, flu syndrome, 
headache, hypertension, infection, and pain. The incidences 
of vasodilatation (hot flushes) and leg cramps were similar 
among the bazedoxifene and raloxifene treatment groups 
and significantly higher than those in the placebo group 
(Table 1). Most cases of vasodilatation were mild to moderate 
in severity and did not lead to discontinuation of therapy. 
The overall frequencies of cardiovascular events and stroke 
were low, and evenly distributed among the groups. The 
incidence of venous thromboembolic events (deep vein 
thrombosis and/or pulmonary embolism) was higher in the 
active treatment groups than in the placebo group, primarily 
because of an increased incidence of deep vein thrombosis, 
although the overall incidence of venous thromboembolic 
events in the active treatment groups was very low (,1%, 
Table 1).29 There was no significant difference in the inci-
dence of venous thromboembolic events among the baze-
doxifene and raloxifene treatment groups.
Breast and endometrial safety
Breast and endometrial safety is an important issue in the 
clinical development of new SERMs. Special attention was 
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Figure 3 Effects of bazedoxifene on the incidence of new vertebral and nonvertebral fractures over 3 years in patients with postmenopausal osteoporosis. The numbers 
above the bars represent the incidence of fracture (%) in each group.
Note: aP , 0.05 vs placebo.
Adapted from Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: 
Results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23(12):1923–1934, with permission from the American Society for 
Bone and Mineral Research.29
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paid to evaluation of the reproductive tract and breast safety 
in the Phase III studies of bazedoxifene.32
In the 2-year Phase III trial, bazedoxifene was not 
associated with a significant change from baseline in mean 
endometrial thickness compared with placebo. There was no 
consensus diagnosis of endometrial hyperplasia or malig-
nancy in the bazedoxifene and raloxifene groups (Table 1). 
There were no significant differences among the groups in 
the change from baseline in ovarian volume, number or size 
of ovarian cysts, or incidence of ovarian cancer. Reports of 
breast pain and breast cancer were low, and evenly distributed 
among the groups.28,33
In the 3-year Phase III trial, there were no significant 
changes in the mean endometrial thickness from baseline or 
in the incidence of endometrial hyperplasia and endometrial 
carcinoma among the groups (Table 1).29,34 There were no 
clinically important changes from baseline in number or 
size of ovarian cysts among the groups. No significant dif-
ference was reported in incidence of breast cancer among 
the groups. There was a significantly lower incidence of 
fibrocystic breast disease for bazedoxifene compared with 
raloxifene. Mammogram analyses after 24 months of therapy 
revealed that the mean percent changes in breast density from 
baseline were low and did not differ significantly among the 
groups.35 In the 2-year extension study, bazedoxifene showed 
no evidence of endometrial or breast stimulation over 5 years 
of therapy, consistent with findings at 3 years. Fewer cases 
of endometrial carcinoma were reported in the bazedoxifene 
group compared with the placebo group.36
Bazedoxifene-conjugated estrogen 
combination therapy
To achieve an ideal balance of estrogen receptor agonist and 
antagonist activities for optimal menopausal therapy, a novel 
approach of partnering a SERM with estrogens, designated 
the tissue-selective estrogen complex, has recently been 
investigated. Preclinical studies revealed that bazedoxifene 
antagonized estrogen-induced uterine and mammary gland 
stimulation more effectively than other SERMs, ie, ralox-
ifene and lasofoxifene.37,38 A randomized, double-blind, 
placebo-controlled Phase III trial in postmenopausal women 
(n = 3397) examined the effect of bazedoxifene 10, 20, 
or 40 mg combined with conjugated estrogens 0.625 mg 
or 0.45 mg on bone and endometrium as the primary 
endpoint.39–43 In this trial, the bazedoxifene-conjugated 
estrogen combination therapy group showed a statistically 
significant increase in bone mineral density and a decrease 
in bone turnover markers compared with those on placebo.42 
In addition to the favorable effects on bone, bazedoxifene-
conjugated estrogen therapy significantly reduced the 
frequency and severity of hot flushes and improved vulvar-
vaginal atrophy and its symptoms compared with placebo, 
with a good tolerability profile.39–41
Place of bazedoxifene in 
management of postmenopausal 
osteoporosis
To date, several different types of drugs have been 
approved for the treatment of osteoporosis. Among them, 
bisphosphonates are generally considered as first-line 
therapy for most patients with osteoporosis. Many stud-
ies have shown that bisphosphonates increase the bone 
mineral density and reduce the incidence of fractures in 
patients with osteoporosis.44–46 However, upper gastroin-
testinal tract adverse effects, such as nausea, dyspepsia, 
abdominal pain, and esophagitis, are common with the 
use of oral bisphosphonates, resulting in discontinuation 
of treatment.46–48 In addition, long-term bisphosphonate 
therapy is associated with osteonecrosis of the jaw, 
defined as exposed nonviable jaw bone, and resistant to 
treatment.46–50
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Hormone replacement therapy was widely recommended 
for treatment of osteoporosis, as well as for relief of 
menopausal symptoms.7,8 However, a large clinical trial 
revealed that long-term use of hormone replacement therapy 
increased the risks of breast cancer and stroke.9 Consequently, 
hormone replacement therapy is not usually recommended as 
a first-line therapy for long-term prevention of osteoporosis 
in women.
Teriparatide, as a recombinant human parathyroid 
hormone (PTH1-34), is an anabolic agent that stimulates 
bone formation and has the potential to improve skeletal 
microarchitecture. It has been demonstrated that teriparatide 
increases bone mineral density and significantly reduces 
fracture risk.51–53 However, the use of teriparatide is limited to 
patients with severe osteoporosis, because it is administered 
by daily subcutaneous injection and is much more expensive 
than other drugs used for osteoporosis.
Raloxifene is the first SERM approved for the prevention 
and treatment of postmenopausal osteoporosis. Raloxifene 
has been shown to increase bone mineral density and reduce 
the risk of vertebral fracture.14–16 In addition to its favorable 
effects on bone, raloxifene reduces the risk of invasive breast 
cancer and decreases low-density lipoprotein cholesterol 
levels.14–16,54,55 The adverse effects of raloxifene treatment 
are an increased risk of venous thromboembolism and an 
increased incidence of vasomotor symptoms.15,16 Owing to 
the limited clinical data for fracture compared with those of 
bisphosphonates and the potential for serious adverse events, 
raloxifene is generally considered as a second-line therapy 
for women with postmenopausal osteoporosis.6,56,57
Bazedoxifene also showed an increase in bone mineral 
density and a reduction of risk of vertebral fractures in osteo-
porotic patients, without stimulating the endometrium or 
breast.28,29 The incidence of nonvertebral fractures in women 
at a higher fracture risk was also reduced by bazedoxifene 
compared with placebo or raloxifene.29 Bazedoxifene was 
shown to inhibit conjugated estrogen-induced responses in 
the uterine and mammary glands in animal models more 
effectively than other SERMs.37,38 Taking advantage of the 
favorable effects of bazedoxifene on the breast and endo-
metrium, the tissue-selective estrogen complex that pairs 
bazedoxifene with conjugated estrogens is currently under 
clinical evaluation for the treatment of osteoporosis and 
menopausal symptoms.
Conclusion
Two global Phase III trials have shown the effective-
ness of bazedoxifene in the prevention and treatment of 
postmenopausal osteoporosis without stimulating the 
endometrium and breast. Although bazedoxifene is a 
promising new therapy for patients with osteoporosis, 
further clinical investigations of long-term treatment 
with this SERM are needed to evaluate the prevention of 
osteoporotic fractures, breast cancers, endometrial cancers, 
and cardiovascular events. When treating patients with 
osteoporosis, estrogens and SERMs have effects not only 
on bone metabolism, but also on the breast, endometrium, 
and lipid metabolism. Before starting treatment, a risk–
benefit assessment should be performed for each patient 
with osteoporosis.
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